dabur india (dabind) - icici directcontent.icicidirect.com/mailimages/idirect_dabur_q1fy17.pdf ·...

July 28, 2016

ICICI Securities Ltd | Retail Equity Research

Result Update

Safe bet on ‘natural’ consumer business… • Dabur reported muted numbers on the sales front for Q1FY17 with

growth of 1.2% YoY to | 1923.9 crore whereas operational performance came in ahead of our expectations. The underlying volume growth stood at 4.1%. Adjusting for the impact of Ind AS, net sales came in at | 2102.7 crore (I-direct estimate: | 2264 crore)

• The domestic business grew by 0.5% YoY led by growth of 11.6%, 4.3%, 2% growth in oral care, foods & home care segments, respectively. However, skin care, digestives, OTC, hair care segments witnessed a subdued performance. Health supplements reported volume growth of 6.7% but flattish sales growth

• EBITDA margins improved 130 bps to 17.9% (I-direct estimate: 16.2%) mainly due to judicious A&P (down 161 bps as percentage of sales) & soft input costs (down 106 bps as percentage of sales). However, higher employee cost partially offset the above savings

• PAT increased 11.8% YoY to | 292.8 crore (I-direct estimate: | 300.3 crore) aided by higher EBITDA & 27.8% YoY increase in other income to | 61 crore

Presence in niche categories to aid in steady revenue growth Dabur India (DIL) has a strong portfolio of brands (Dabur Chyawanprash, Real, Hajmola, Vatika, Amla, Fem, Honey, Meswak, Dabur Red) with the focus largely on ayurvedic & healthcare offerings. The company’s diverse product portfolio (hair care, oral care, skin care, home care, health supplements, digestives, OTC & ethicals) and presence in niche categories has aided revenue growth at a robust 18.6% CAGR in FY09-15. Led by DIL’s brand strength in higher growth niche segments & further strengthening of the portfolio through new launches focusing on healthcare, we estimate revenue growth at 10.8% CAGR in FY16-18E. Direct beneficiary of normal monsoon with strong presence in rural areas In the last few years (FY11-15), DIL has augmented its rural reach from ~14,000 villages to ~45,000 villages through its ‘Project Double’. The initiative played out extremely well for DIL by increasing contribution to booming rural demand in revenues to 45% from ~30% earlier. It also aided in maintaining volume growth at 8-11%. Going forward, it intends to reach ~60000 villages by FY17E. With monsoons progressing in a normal manner, we expect DIL to capitalise on a revival in rural consumption as a result of this presence in rural India. Also, with DIL planning to increase its healthcare offerings, it is aiming to increase its urban coverage by capturing the untapped chemist network through a new initiative called ‘Project CORE’. It has increased its chemist network reach from ~31000 (FY13) to ~75000 in FY15. Quarterly blip does not impact long term growth potential; maintain BUY Since its inception, DIL has efficiently leveraged ayurveda & herbal product offerings to its advantage. DIL’s portfolio of traditional products, the category that has piqued consumer interest in recent times, straddles from Meswak, premium herbal toothpaste, to recently launched Hajmola Yoodley, an ethnic beverage to capture fast growing segment of traditional beverages. Thus, we believe DIL is in a healthy position to capitalise on tailwinds generated for demand of ayurvedic & herbal products in the Indian FMCG market. We expect DIL to clock sales growth of 10.8% CAGR in FY16-18E on the back of ~8% volume growth. We estimate earnings CAGR of 14.7% in FY16-18E. We reiterate BUY recommendation on the stock with a target price of | 338/share.

Dabur India (DABIND) | 304 Rating matrix

Rating : BuyTarget : | 338Target Period : 12 monthsPotential Upside : 11%

What’s changed? Target Changed from | 304 to | 338EPS FY17E Changed from | 7.9 to | 8.0EPS FY18E Changed from | 8.6 to | 9.4Rating Unchanged

Quarterly performance

Q1FY17 Q1FY16 YoY (%) Q4FY16 QoQ (%)Sales 1923.9 1901.7 1.2 1980.0 -2.8EBITDA 344.3 315.7 9.1 411.2 -16.3EBITDA (%) 17.9 16.6 130 bps 20.8 -287 bpsPAT 292.8 261.8 11.8 331.5 -11.7

Key financials

| Crore FY15 FY16 FY17E FY18ENet Sales 7,806.4 7,761.6 8,579.3 9,536.4 EBITDA 1,316.4 1,518.3 1,711.4 1,990.9 Net Profit 1,071.1 1,251.2 1,407.9 1,646.7 EPS (|) 6.1 7.1 8.0 9.4

*From FY16 onwards, financials are reported as per Ind AS Valuation summary

FY15 FY16 FY17E FY18EP/E 49.9 42.7 38.0 32.5 Target P/E 55.4 47.5 42.2 36.1 Div. Yield 0.8 0.8 1.0 1.4 Mcap/Sales 6.8 6.9 6.2 5.6 RoNW (%) 31.9 30.2 27.9 27.7 RoCE (%) 31.8 31.1 29.7 29.9

*From FY16 onwards, financials are reported as per Ind AS Stock data Particular AmountMarket Capitalization (| Crore) 51,641.1Total Debt (FY16) (| Crore) 668.0Cash and Investments (FY16) (| Crore) 954.9EV (| Crore) 51,354.252 week H/L 320 / 232Equity capital | 175.9 CroreFace value | 1 Price performance

1M 3M 6M 12MDabur -3.4 13.0 29.8 3.8Marico 8.3 11.2 30.1 30.2GCPL 5.7 17.9 40.6 32.5HUL 5.1 1.2 17.7 0.3 Research Analyst

Sanjay Manyal [email protected]

Parth Joshi

[email protected]


Result Update

Variance analysis Q1FY17 Q1FY17E Q1FY16 YoY (%) Q4FY16 QoQ (%) Comments

Net Sales 1,923.9 2,264.0 1,901.7 1.2 1,980.0 -2.8 Dabur reported tepid net sales growth of 1.2% on the back of 4.1% volume

growth in its India FMCG business. Oral care, foods & home care segment

grew 11.6%, 4.3% & 2%, respectively. Foods business reported volume

growth of 7% while health supplements' volumes grew 6.7% but sales came

in flat. Skin care, digestives & OTC segments reported a decline in salesOperating Income 4.5 4.7 5.4 -15.8 4.0 13.9

Raw Material Expenses 937.6 1,053.6 946.9 -1.0 968.4 -3.2 Raw material cost for the company dipped 106 bps as a percentage of salesdue to benign commodity prices

Employee Expenses 211.5 210.6 189.0 11.9 201.8 4.8 Employee cost increased 105 bps as percentage of salesSG&A Expenses 196.5 335.1 224.7 -12.5 154.0 27.6 A&P spend declined 161 bps as percentage of salesOther operating Expenses 234.0 229.8 225.4 3.8 244.6 -4.3

EBITDA 344.3 367.0 315.7 9.1 411.2 -16.3EBITDA Margin (%) 17.9 16.2 16.6 130 bps 20.8 -287 bps Operating margins improved 130 bps mainly due to lower A&PDepreciation 34.3 35.9 32.5 5.6 35.8 -4.1Interest 11.8 12.2 11.8 0.2 13.2 -10.3Other Income 61.0 61.4 47.7 27.8 53.9 13.3

PBT 363.7 385.0 324.4 12.1 420.1 -13.4Tax Outgo 70.1 84.7 62.0 13.1 86.8 -19.2PAT 292.8 300.3 261.8 11.8 333.3 -12.1 Higher EBITDA as well as higher other income drove PAT by 11.8% YoY

Key Metrics YoY growth (%)Volume Growth 4.1 NA 8.1 7.0Standalone sales growth 0.5 8.0 10.5 9.1 Dabur Honey range was extended to premium honey fruit spreads priced at |

120-130 & | 240-270 for 170 gm & 370 gm, respectively. Real VOLO, a carbonated fruit-based drink was launched at | 40 for 250 ml can. Mosambi variant was added to Real fruit juice range while mixed fruit variant was added to Real Activ range

Subsidiary's sales growth 6.0 13.1 11.3 15.6 Dermoviva facial fluids, Dermoviva body lotion, Dermoviva face cream & Hazmazza saw addition of variants in Q1FY17

Source: Company, ICICIdirect.com Research Change in estimates

(| Crore) Old New % Change Old New % Change CommentsSales 9,366.6 8,579.3 -8.4 10193.9 9536.4 -6.4 We have incorporated impact of Ind AS in our sales & margins estimatesEBITDA 1,666.0 1,692.4 1.6 1821.6 1971.0 8.2EBITDA Margin (%) 17.8 19.7 194 bps 17.9 20.7 280 bpsPAT 1,390.4 1,407.9 1.3 1509.7 1646.7 9.1EPS (|) 7.9 8.0 1.3 8.6 9.4 9.1

FY18EFY17E

Source: Company, ICICIdirect.com Research Assumptions

FY14 FY15E FY16E FY17E FY18E FY16E FY17E FY18EStd. Sales (| crore) 4,860.4 5,418.9 5,329.7 5,824.3 6,427.2 5,739.6 6,241.7 6,769.3Volume Growth (%) 9.3 8.0 NA NA NA NA NA NASubs. Sales (| crore) 2,207.9 2,387.5 2,431.9 2,755.1 3,109.2 2,696.3 3,124.9 3,424.6

RM exp. To sales % 48.1 47.7 48.4 48.4 48.9 45.0 45.9 46.6Adex to sales % 14.1 14.4 9.9 9.9 10.5 14.7 14.4 14.8Interest Cost (| crore) 54.2 40.1 48.5 49.0 46.5 48.0 49.0 47.4

Current Earlier

Source: Company, ICICIdirect.com Research


Result Update Company Analysis Revenue growth to remain stable largely led by volumes & initiatives DIL’s revenue growth has remained robust at 18.6% CAGR (FY09-15) buoyed by its diverse & niche product portfolio, a slew of product launches and synergistic inorganic acquisitions (Fem in FY09, Namaste in FY11, Hobi in FY11) both in the domestic as well as international markets. Even in a slowing consumer demand scenario from H2FY13, DIL managed to maintain its healthy revenue growth of 12-16% led by volume growth of 8-11% until Q2FY16. The slowdown, however, largely impacted the company’s hair oil (segment as a whole witnessing stagnation in growth) & skin care growth (impacted by lower discretionary demand). Of late, there was intense competition in health supplements (Dabur Chyawanprash, Dabur Honey) mainly due to entry of Patanjali (while keeping the oral care (Meswak & Dabur Red), home care (Odonil, Odomos), foods (Real, Real Activ), digestive (Hajmola) and OTC & ethicals portfolio growth healthy. DIL launched ‘Project 50:50’ in FY15 wherein it will focus on top 130 cities in India that contribute 50% of urban consumption to drive revenues. Under this initiative, Dabur will split the sales team for wholesale & retail channels to better tap the demand in urban markets. According to the company, most of these cities are in South India, which contribute 15-20% of total revenue for Dabur. Dabur launched ‘Project LEAD’ in FY16 under which front-end teams will be separated for healthcare & other domestic FMCG business to enable better focus on these segments. For this purpose, DIL would hire ~275 medical representatives. DIL expects annual cost of ~| 10-12 crore towards Project LEAD. Dabur forayed into the ayurvedic hair oil segment with the launch of Keratex (previously a pharma product but now an OTC product) in FY15. DIL launched Dabur Honey fruit spread (four variants), carbonated fruit-based beverage Real VOLO, additional variants under Real & Real Activ fruit juices in domestic market & additional variants under Dermoviva facial fluids, body lotion, face cream & under Hazmazza in international markets in Q1FY17. Riding on the back of promotions, DIL’s entry into honey fruit spreads is expected to drive premiumisation in the honey segment and hence, combat an indigenous rival that has entered honey category with deep discount pricing model. Going ahead, we believe the company’s increasing focus on innovations and strengthening presence both in rural and urban India would aid volumes. We expect revenue growth at 10.8% CAGR in FY16-18E, largely led by volumes. Exhibit 1: Revenues (| crore) and revenue growth (%) trend

3390.5 4077.4 5305.4 6146.7 7073.2 7806.4 7761.6 8579.3 9536.4

20.9 20.3

30.1

15.9 15.1

10.4

-0.6

10.5 11.2

0

2000

4000

6000

8000

10000

12000

FY10 FY11 FY12 FY13 FY14 FY15 FY16E FY17E FY18E

-5

0

5

10

15

20

25

30

35

Sales (| crore) Sales growth (%)

Source: Company, ICICIdirect.com Research *From FY16 onwards, financials are reported as per Ind AS


Result Update Exhibit 2: Category wise revenue growth in percentage (YoY)

Q3FY13Q4FY13 FY13 Q1FY14 Q2FY14 Q3FY14 Q4FY14 FY14 Q1FY15 Q2FY15 Q3FY15 Q4FY15 FY15 Q1FY16 Q2FY16 Q3FY16 Q4FY16 Q1FY17Hair Care 13.9 9.6 11.7 11.8 3.9 7.0 6.0 7.1 8.4 10.2 12.1 7.4 10.3 12.7 9.4 2.0 8.2 NAOral Care 13.6 12.3 10.4 8.6 18.8 10.4 17.3 13.8 8.0 8.1 11.3 11.6 9.8 17.5 18.7 10.5 18.3 11.6Health Supp. 12.0 22.6 16.2 7.5 16.7 19.5 17.6 16.4 21.6 10.1 13.5 13.0 13.9 1.2 9.0 -7.1 NA NADigestives -5.4 1.3 3.9 15.2 12.0 17.7 23.3 17.2 11.3 12.3 11.6 11.0 11.5 1.7 1.6 -2.4 6.5 NASkin Care 15.7 11.1 15.3 13.3 17.5 13.4 10.1 13.2 4.4 9.7 4.0 16.6 8.3 5.2 2.2 9.5 NA NAHome Care 30.5 33.3 25.3 25.6 25.1 16.0 12.8 19.8 14.7 10.2 16.2 12.1 13.2 12.0 12.4 8.4 19.3 2.0Foods 22.2 22.6 24.5 18.7 22.0 17.6 20.6 19.7 21.6 29.0 11.8 19.6 20.2 15.5 2.4 -23.7 11.7 4.3OTC & Ethicals 15.6 13.7 16.1 11.8 11.2 13.2 10.9 11.8 4.4 7.5 8.8 7.7 7.3 16.7 10.8 7.5 7.1 NARetail 32.8 28.5 43.9 27.1 17.7 14.7 20.4 19.6 NA NA NA NA NA NA NA NA NA NA


EBITDA margins to remain healthy at 20.7% by FY18E…

DIL’s margins have remained at higher levels of 16-18% since FY08 led by the company’s strong brand equity in the healthcare space of the FMCG segment. Along with a changing sales mix (more towards the products witnessing constant demand than seasonal demand), Dabur has efficiently managed its raw material expenses and marketing expenses in order to sustain its margins. Going ahead, with continued focus on the healthcare portfolio, aggressive expansion through new launches, expansion in reach & change in sales mix, we believe margins would remain sturdy at 20.7% by FY18E. We believe that aided by the company’s ability to sustain a high brand equity in its segments, fluctuations in raw material cost, if any, will be absorbed efficiently without impacting margins. However, we believe that any savings in raw material costs would be directed towards higher advertisement & promotion expenses.

Exhibit 3: EBITDA margin (%), RM cost to sales (%) and adex to sales (%) trend

16.618.6 18.5

16.8 17.418.5

15.4

20.7

14.116.5 17.0 16.3

14.3

16.4 16.0 16.6

19.3 19.7

0

10

20

30

40

50

60

FY09 FY10 FY11 FY12 Q1FY13 Q2FY13 Q3FY13 Q4FY13 FY13 Q1FY14 Q2FY14 Q3FY14 Q4FY14 FY14 FY15 FY16 FY17E FY18E

0

5

10

15

20

25

RM Cost to Sales EBITDA Margins Adex to Sales



Result Update Expansion in distribution network to augur well for future DIL has efficiently expanded its distribution network in rural India through ‘Project Double’ since FY11. Through Project Double, the company expanded its reach from ~14000 villages in FY11 to ~45000 villages in FY15. The extension in rural India paid off well for the company in capturing booming rural demand in India in FY11-14. With initial signs of softening rural demand following a weak economic scenario and slow urban demand recovery, going ahead, the company limited its rural reach since FY14, and now plans to consolidate its position further. It plans to increase the number of SKUs in existing rural distribution centres and increase its offerings in existing rural markets along with a few new launches. Dabur plans to extend its rural reach to ~60,000 villages by FY17E. On the urban front, DIL is aiming to increase its presence in the chemist channels of distribution considering the healthcare focus of the company’s portfolio. Following the target to increase chemist coverage, DIL launched ‘Project CORE – Chemist Outlet and Range Expansion’ in FY14. Further, the company increased its chemist distribution points from ~31,000 outlets (FY13) to ~75,000 outlets in FY15. Dabur launched ‘Project LEAD – Leveraging through Empowered Anchoring & Detailing’ in Q1FY16 under which the front end teams will be separated for healthcare (OTC & ethicals) and other domestic FMCG business to enable better focus on these segments. With DIL’s strength of implementation, we believe the company’s constant focus on managing sales and distribution efficiently in both urban and rural markets along with a strong innovation pipeline, revenue and margin growth would continue to remain stable. Ayurveda, herbal products remain ace up Dabur’s sleeve Dabur, having been present in India for more than 125 years, has built its strong edifice by leveraging on Ayurveda & herbal product offerings. The recent rise of Patanjali Ayurveda has been able to garner public attention towards herbal offerings & products of Ayurvedic origin. Though it has resulted in disruptive competition in many categories in which the company is present, we believe Dabur is well equipped with its array of brands with high consumer recall to counter its rivals. DIL’s portfolio of traditional products, the category that has piqued consumer interest in recent times, straddles from Meswak, a premium toothpaste under the herbal segment, to the recently launched Hajmola Yoodley, an ethnic beverage to capture the fast growing segment of traditional beverages. Thus, we believe that on the back of strong brand equity enjoyed by its products, DIL is in a healthy position to capitalise on the tailwinds generated for demand of Ayurvedic & herbal products in the Indian FMCG market due to the ‘Patanjali’ phenomenon.


Result Update Outlook & valuation We believe DIL’s strong and niche product portfolio would continue to generate stable revenue and earnings growth at 10.8% and 14.7% CAGR in FY16-18E. Further, the increase in distribution expansion and constant innovation would be catalysed if there is a revival in consumer demand. We believe that given the diverse product portfolio, the company’s margins would remain sustainable and less prone to fluctuations in raw material prices. Hence, we remain positive on the long term outlook of the company. The only concern for us remains the challenging near term consumer demand scenario. However, the progress of monsoon as per expectations and other government measures to kick start rural growth engine remain key triggers to a rural demand revival in the medium-term. Successful resolution of the Nepal border blockade issue has relieved DIL of the hiccups it faced in sales growth in FY16. We believe that continuous innovation to counter moderating growth and aggressive expansion in distribution network would lead to stable volume growth, going forward. We believe sales growth in the domestic business would revive, going forward and expect robust margins at 20.7% by FY18E. Given DIL’s strong brands & market development of the niche segments (packaged foods & juices, health supplements) and revival in urban demand, valuation multiples will command a premium to its historic averages. We value the stock at 36x FY18E EPS of | 9.4 and arrive at a target price of | 338. We maintain BUY recommendation. Exhibit 4: Valuations

Sales Growth EPS Growth PE EV/EBITDA RoNW RoCE (| cr) (%) (|) (%) (x) (x) (%) (%)

FY15 7806.4 10.4 6.1 15.7 49.9 41.5 31.9 31.8FY16 7761.6 -0.6 7.1 16.6 42.7 35.9 30.2 31.1FY17E 8579.3 10.5 8.0 12.5 38.0 31.9 27.9 29.7FY18E 9536.4 11.2 9.4 17.0 32.5 27.2 27.9 30.1



Result Update Recommendation history vs. Consensus

100

200

300

400

Jul-16May-16Mar-16Dec-15Oct-15Jul-15May-15Feb-15Dec-14Sep-14Jul-14

(|)

0.010.020.030.040.050.060.070.080.090.0100.0

(%)

Price Idirect target Consensus Target Mean % Consensus with BUY

Source: Bloomberg, Company, ICICIdirect.com Research Key events Date EventNov-08 Acquisition of the company's largest skin care brand 'Fem' from Fem Care Pharma marking its entry in the high growth skin care segmentJul-09 Rise in stock price following the increase in FMCG Index led by attractiveness of defensives in the economic downturnApr-10 Consistent 18-20% revenue growth with improvement in margins to ~20% tapping the revival in consumption demand

Jul-10Enters Turkey through acquisition of Hobi Kozmetik for | 324 crore. Acquisition is in line with the company's strategy of strengthening its presence in Middle East & North Africa

Sep-10 Dabur issues bonus in the ratio of 1:1

Jan-11Acquires US based personal care firm Namaste Laboratories LLC for | 451 crore. Acquisition marked Dabur's entry into US$1.5 billion hair care markets of US, Europe and Africa

Mar-11 Launches 'Project Double' to double its direct reach in villages and to tap the growing aspirational demand of rural consumersMay-12 Stock performance remaines lacklusture due to falling domestic revenues, declining margins and no significant innovations

May-13In a grim economic scenario, ability to grow in double digits (volume) along with improvement in margins and market share gains across categories made it the top preferred stock in the FMCG pack

Mar-14 Launches 'Project CORE' to increase its distribution footprint in the chemist channelJun-15 Launches 'Project LEAD' to enable better focus on healthcare (OTC & ethicals) & other domestic FMCG business

Source: Company, ICICIdirect.com Research Top 10 Shareholders Shareholding Pattern Rank Name Latest Filing Date % O/S Position (m) Change (m)1 Chowdhry Associates 31-Mar-16 12.37 217.9 0.02 VIC Enterprises Pvt. Ltd. 31-Mar-16 12.36 217.7 0.03 Gyan Enterprises Pvt. Ltd. 31-Mar-16 11.48 202.2 0.04 Puran Associates Pvt. Ltd. 31-Mar-16 10.74 189.2 0.05 Ratna Commercial Enterprises Pvt. Ltd. 31-Mar-16 8.88 156.4 0.06 Milky Investment & Trading Co., 31-Mar-16 6.03 106.1 0.07 Life Insurance Corporation of India 31-Mar-16 3.26 57.5 0.08 Burmans Finvest Pvt. Ltd. 31-Mar-16 3.01 53.0 0.09 Matthews International Capital Management, L.L.C. 31-Mar-16 1.76 31.0 0.210 First State Investments (HK) Ltd. 31-Mar-15 1.53 26.9 4.0

(in %) Jun-15 Sep-15 Dec-15 Mar-16 Jun-16Promoter 68.2 68.1 68.1 68.1 68.0FII 21.1 21.0 20.4 19.6 19.9DII 4.6 4.4 4.7 5.5 5.4Others 6.1 6.5 6.8 6.8 6.7

Source: Reuters, ICICIdirect.com Research Recent Activity

Investor name Value Shares Investor name Value SharesAPG Asset Management 13.99m 3.34m Harding Loevner LP -19.97m -5.29mÖKOWORLD LUX S.A. 9.41m 2.27m Aberdeen Asset Management (Asia) Ltd. -16.1m -3.73mNorges Bank Investment Management (NBIM) 7.8m 1.86m Grantham Mayo Van Otterloo & Co LLC -5.79m -1.66mPictet Asset Management Ltd. 4.75m 1.26m Schroder Investment Management (Hong Kong) Ltd. -2.4m -0.64mDNB Asset Management (Asia) Limited 4.07m 0.94m Handelsbanken Asset Management -2.19m -0.53m

Buys Sells

Source: Reuters, ICICIdirect.com Research


Result Update .

Financial summary Profit and loss statement | Crore (Year-end March) FY15 FY16 FY17E FY18ENet Sales 7806.4 7761.6 8579.3 9536.4Growth (%) 10.4 -0.6 10.5 11.2Raw Material Expenses 3,720.1 3,760.5 4,150.1 4,665.6Employee Expenses 689.6 794.1 883.7 892.2Marketing Expenses 1,124.4 771.6 849.4 900.8Administrative Expenses 679.7 0.0 0.0 0.0Other expenses 297.1 935.2 1,003.8 1,106.7Total Operating Expenditure 6,510.8 6,261.4 6,886.9 7,565.4EBITDA 1295.6 1500.2 1692.4 1971.0Growth (%) 14.1 15.8 12.8 16.5Depreciation 115.0 133.2 145.7 153.5Interest 40.1 48.5 49.0 46.5Other Income 158.1 217.2 243.3 267.6PBT 1,319.4 1,553.8 1,759.9 2,058.4Others 0.0 0.0 0.0 0.0Total Tax 250.9 299.9 352.0 411.7PAT 1071.1 1251.2 1407.9 1646.7Growth (%) 16.6 16.8 12.5 17.0Adjusted EPS (|) 6.1 7.1 8.0 9.4


Cash flow statement | Crore (Year-end March) FY15 FY16 FY17E FY18EProfit before Tax 1,319.4 1,553.8 1,759.9 2,058.4Add: Depreciation 115.0 133.2 145.7 153.5(Inc)/dec in Current Assets -143.3 -615.9 -381.1 -489.6Inc/(dec) in CL and Provisions 24.9 51.4 42.9 102.0Others -268.8 -232.8 -303.0 -365.2CF from operating activities 1,047.2 889.7 1,264.5 1,459.2(Inc)/dec in Investments -625.1 -378.0 -110.0 -220.0(Inc)/dec in Fixed Assets -251.1 -201.0 -520.0 -120.0Others 0.0 0.0 0.0 0.0CF from investing activities -876.2 -578.9 -630.0 -340.0Issue/(Buy back) of Equity 45.5 0.3 0.0 0.0Inc/(dec) in loan funds 25.4 126.8 -60.0 -120.0Dividend paid & dividend tax -394.8 -447.0 -527.7 -791.6Inc/(dec) in Sec. premium 0.0 0.0 0.0 0.0Others -92.9 -48.5 -49.0 -46.5CF from financing activities -416.8 -368.5 -636.7 -958.1Net Cash flow -245.8 -57.7 -2.2 161.1Opening Cash 519.4 276.0 218.3 216.1Closing Cash 276.0 218.3 216.1 377.2


Balance sheet | Crore (Year-end March) FY15 FY16 FY17E FY18ELiabilitiesEquity Capital 175.7 175.9 175.9 175.9Reserve and Surplus 3,178.5 3,982.6 4,862.8 5,717.9Total Shareholders funds 3,354.1 4,158.5 5,038.7 5,893.9Long Term Loans 210.6 341.5 341.5 321.5Long Term Provisions 58.7 76.5 76.5 76.5Minority Interest / Others 64.4 72.7 72.6 72.7Total Liabilities 3,687.8 4,649.2 5,529.3 6,364.5AssetsGross Block 2,566.6 2,889.3 3,389.3 3,489.3Less: Acc Depreciation 760.9 894.1 1,039.8 1,193.3Net Block 1,805.8 1,995.2 2,349.5 2,296.0Capital WIP 121.7 0.0 20.0 40.0Non- Current Investments 1,407.4 1,787.3 1,887.3 2,087.3LT loans & advances 20.8 29.5 89.5 189.5Other Non-current Assets 20.1 18.2 28.2 48.2Current AssetsInventory 973.3 1,096.5 1,239.2 1,404.0Debtors 710.8 809.7 905.6 1,086.1Cash & Bank 276.0 218.3 216.1 377.2ST Loans & Advances 278.9 326.5 429.0 503.3Other Current Assets 491.6 837.7 877.7 947.7Current LiabilitiesCreditors 1,095.8 1,330.2 1,263.1 1,245.0ST Borrowings 523.0 449.7 499.7 559.7Other CL 799.7 689.9 749.9 809.9Net Current Assets 312.1 818.9 1,154.8 1,703.5Total Assets 3,687.8 4,649.2 5,529.3 6,364.5


Key ratios (Year-end March) FY15 FY16 FY17E FY18EPer share data (|)Adjusted EPS 6.1 7.1 8.0 9.4Cash EPS 6.8 7.9 8.8 10.2BV 19.1 23.6 28.6 33.5DPS 2.0 2.3 3.0 4.5Cash Per Share 1.6 1.2 1.2 2.1Operating Ratios (%)PBITDA Margin 16.8 19.5 19.9 20.8PBT / Total Operating income 14.9 17.2 17.7 18.8PAT Margin 13.7 16.2 16.4 17.3Inventory days 45 51 52 53Debtor days 33 38 38 41Creditor days 51 62 53 47Return Ratios (%)RoE 31.9 30.2 27.9 27.9RoCE 31.8 31.1 29.7 30.1RoIC 31.3 28.3 27.3 29.0Valuation Ratios (x)P/E 49.9 42.7 38.0 32.5EV / EBITDA 41.5 35.9 31.9 27.2EV / Net Sales 6.9 6.9 6.3 5.6Market Cap / Sales 6.8 6.9 6.2 5.6Price to Book Value 15.9 12.9 10.6 9.1Solvency RatiosDebt/EBITDA 0.6 0.5 0.5 0.4Debt / Equity 0.2 0.2 0.2 0.1Current Ratio 1.3 1.5 1.7 1.9Quick Ratio 0.8 1.0 1.1 1.2



Result Update

ICICIdirect.com coverage universe (FMCG) CMP M Cap(|) TP(|) Rating (| Cr) FY16E FY17E FY18E FY16E FY17E FY18E FY16E FY17E FY18E FY16E FY17E FY18E FY16E FY17E FY18E

Colgate (COLPAL) 931 940 Buy 22,709 21.2 23.5 26.9 43.9 39.6 34.7 5.5 4.9 4.3 77.6 73.6 73.5 58.7 51.6 51.4Dabur India (DABIND) 304 338 Buy 2,975 7.1 8.0 9.4 42.7 38.0 32.5 6.9 6.2 5.6 31.1 29.7 30.1 30.2 27.9 27.9GSK CH (GLACON) 6,353 6,966 Buy 24,467 163.3 173.2 196.5 38.9 36.7 32.3 5.7 5.0 4.4 37.3 36.6 36.5 26.6 26.5 26.6Hindustan Unilever (HINLEV) 909 1,000 Buy 195,335 19.1 21.7 24.7 47.6 42.0 36.8 6.4 5.9 5.4 106.8 199.0 219.8 111.1 175.4 198.0ITC Limited (ITC) 254 277 Buy 301,589 7.7 8.8 10.0 33.0 28.9 25.5 5.8 5.2 4.7 42.2 46.0 49.1 28.7 31.8 35.1Jyothy Lab (JYOLAB) 289 300 Hold 5,272 9.0 9.9 11.2 32.2 29.3 25.8 3.4 3.0 2.7 19.2 17.9 19.5 15.7 15.4 16.7Marico (MARIN) 283 285 Buy 33,480 5.6 6.4 7.9 50.4 44.1 35.7 5.5 5.0 4.3 46.3 45.6 46.7 34.6 34.4 36.0Nestle (NESIND) 7,237 6,615 Buy 57,679 58.4 120.9 164.5 123.9 59.8 44.0 7.1 5.4 4.7 29.7 36.1 41.6 32.3 38.1 44.7Tata Global Bev (TATTEA) 140 115 Hold 7,513 5.2 6.5 7.0 27.1 21.6 20.0 0.9 0.9 0.8 7.7 8.5 8.8 5.6 6.9 7.2VST Industries (VSTIND) 1,954 1,931 Buy 2,651 99.2 115.8 128.9 19.7 16.9 15.2 3.0 2.8 2.5 59.7 65.0 67.7 41.3 45.2 47.0

Sector / CompanyRoE (%)EPS (|) P/E (x) Price/Sales (x) RoCE (%)



Result Update

RATING RATIONALE ICICIdirect.com endeavours to provide objective opinions and recommendations. ICICIdirect.com assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock. Strong Buy: >15%/20% for large caps/midcaps, respectively, with high conviction; Buy: >10%/15% for large caps/midcaps, respectively; Hold: Up to +/-10%; Sell: -10% or more;

Pankaj Pandey Head – Research [email protected]

ICICIdirect.com Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093

[email protected]


Result Update

ANALYST CERTIFICATION We /I, Sanjay Manyal, MBA (Finance) and Parth Joshi, MBA (Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Terms & conditions and other disclosures: ICICI Securities Limited (ICICI Securities) is a Sebi registered Research Analyst having registration no. INH000000990. ICICI Securities is full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities is a wholly-owned subsidiary of ICICI Bank which is India’s largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. (“associates”), the details in respect of which are available on www.icicibank.com ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction. ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months. ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts have any material conflict of interest at the time of publication of this report. It is confirmed that Sanjay Manyal, MBA (Finance) and Parth Joshi, MBA (Finance), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ICICI Securities or its subsidiaries collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. It is confirmed that Sanjay Manyal, MBA (Finance) and Parth Joshi, MBA (Finance), Research Analysts do not serve as an officer, director or employee of the companies mentioned in the report. ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report. We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

dabur india (dabind) - icici directcontent.icicidirect.com/mailimages/idirect_dabur_q1fy17.pdf ·...

Documents